Weekly EGID Research Digest: CEDP Colonic Panel, Beyond Eosinophil Depletion & TSLP Phase 3 (2026-W45)

Introduction: Longitudinal Evidence & Translational Tracking

Welcome to the weekly research digest from the EGID Research & Clinical Trial Database.

Eosinophilic Gastrointestinal Diseases (EGID)—encompassing Eosinophilic Gastroenteritis (EGE), Gastritis (EoG), Colitis (EoC), and Esophagitis (EoE)—are entering a transformative therapeutic era. The convergence of targeted monoclonal antibodies (targeting IL-4, IL-5, IL-13, and TSLP pathways), high-precision molecular transcriptomic profiling, and longitudinal patient telemetry is providing unprecedented insights into previously refractory patient subsets.

This weekly briefing synthesizes newly indexed PubMed publications, international trial registrations, and translational insights.

---

1. Newly Indexed Clinical & Translational Studies

1. Precision Diagnosis and Differentiation of Eosinophilic Colitis and Inflammatory Bowel Disease Using a Tissue-Based Molecular Gene Expression Panel

• Journal/Registry: The Journal of Allergy and Clinical Immunology (JACI) (PMID: 42950958)
• Target Conditions: 好酸球性大腸炎 (EoC), 炎症性腸疾患 (IBD), 潰瘍性大腸炎 (UC), 好酸球性消化管疾患 (EGID)
• Authors / Sponsor: Taylor RJ, Yamaguchi M, Denson LA
• Link: PMID: 42950958

Key Clinical Findings:

• 好酸球性大腸炎（EoC）と炎症性腸疾患（IBD：潰瘍性大腸炎やクローン病）で好酸球増多を伴う症例は、従来の生検鏡検や臨床症状が重複し誤診・診断遅延が頻発していた課題に対し、96遺伝子qPCRパネル（CEDP）を開発・検証。
• 好酸球関連遺伝子（CLC等）59遺伝子からなるEoCスコア（AUC 0.92）と、IBD炎症経路（DUOXA2等）を反映する18遺伝子のIBDスコアを組み合わせた2成分分子フレームワークを構築。
• この分子プロファイリングにより、組織好酸球浸潤が高いIBDと活動性EoCを極めて高精度（AUC 0.99、95% CI 0.95-1.0）に峻別可能となり、従来の光学顕微鏡病理の限界を超える分子病理診断基盤が確立。

💡 Patient & Translational Perspective:

Highlights the ongoing paradigm shift in EGID management from empiric immunosuppression toward endotype-driven biologic therapy and longitudinal mucosal monitoring.

---

2. Beyond Eosinophil Depletion: Toward Multidimensional Remission in Eosinophilic Gastritis and Duodenitis

• Journal/Registry: Clinical and Experimental Gastroenterology (PMID: 42928781)
• Target Conditions: 好酸球性胃炎 (EoG), 好酸球性十二指腸炎 (EoD), 好酸球性胃腸炎 (EGE), 好酸球性消化管疾患 (EGID)
• Authors / Sponsor: Salman A
• Link: PMID: 42928781

Key Clinical Findings:

• ベンラリズマブ（組織寛解77% vs プラセボ8%）、デュピルマブ（DEGAS試験）、リレンテリマブの第3相治験において、生検での好酸球枯渇と患者報告アウトカム（PRO: 腹痛・悪心症状）の改善が乖離する現象を系統的分析。
• 好酸球密度の低下が必ずしも患者の苦痛消失に直結しない要因として、肥満細胞の残存活性化、神経筋知覚過敏、パッチ状病変による生検サンプリング誤差、慢性炎症に伴う粘膜バリア機能障害を特定。
• 単一の好酸球数による寛解判定を脱却し、「生物学的疾患活動性」「組織構造的損傷」「患者主観的状態（PRO）」の3領域を分離・多次元評価する新たな寛解フレームワークを提言。

💡 Patient & Translational Perspective:

Highlights the ongoing paradigm shift in EGID management from empiric immunosuppression toward endotype-driven biologic therapy and longitudinal mucosal monitoring.

---

3. IL-33/ST2 signalling in pediatric food allergy and eosinophilic gastrointestinal disorders: a systematic review of human and preclinical evidence

• Journal/Registry: Frontiers in Immunology (PMID: 42935742)
• Target Conditions: 好酸球性消化管疾患 (EGID), 好酸球性胃腸炎 (EGE), 好酸球性食道炎 (EoE), 小児食物アレルギー
• Authors / Sponsor: Grama M, Săsăran MO, Stan Muntean A
• Link: PMID: 42935742

Key Clinical Findings:

• 上皮由来アラミンサイトカインIL-33およびその受容体ST2が、小児の難治性食物アレルギーおよび好酸球性消化管疾患（EGID）で果たす役割を体系化したシステマティック・レビュー。
• 前臨床動物モデルにおいて、皮膚角化細胞から放出されたIL-33が血流を介して「皮膚-腸連関（skin-to-gut axis）」を活性化し、腸管内での肥満細胞増殖とIgE非依存性アナフィラキシーを惹起することを解明。
• 小児好酸球性胃腸炎コホートにおいて活動期に血清IL-33およびTSLPが著明に上昇し、食事除去療法後に速やかに低下することを確認、上皮障害と2型炎症を繋ぐ新規活動性バイオマーカーとして浮上。

💡 Patient & Translational Perspective:

Highlights the ongoing paradigm shift in EGID management from empiric immunosuppression toward endotype-driven biologic therapy and longitudinal mucosal monitoring.

---

4. A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING)

• Journal/Registry: AstraZeneca / ClinicalTrials.gov (NCT05583227)
• Target Conditions: 好酸球性食道炎 (EoE), 好酸球性消化管疾患 (EGID)
• Authors / Sponsor: AstraZeneca
• Link: NCT05583227

Key Clinical Findings:

• アストラゼネカ社が主導する、成人および思春期の好酸球性食道炎（EoE）患者を対象とした抗TSLP抗体テゼペルマブ（テゼスパイア）の多施設共同二重盲検プラセボ対照国際第3相臨床試験（CROSSING）。
• 2026年10月30日付で治験ステータスが「Active, not recruiting（患者登録完了・投与追跡フェーズ）」へと正式移行し、主要評価項目である組織学的寛解および嚥下障害症状スコアの最終解析へ前進。
• IL-4やIL-13の下流サイトカイン遮断とは異なり、上皮バリア破壊の起点となるTSLPを直接中和することで、好酸球のみならず肥満細胞や自然リンパ球（ILC2）を含む全カスケードを根底から鎮静化する次世代バイオ製剤として期待。

💡 Patient & Translational Perspective:

Highlights the ongoing paradigm shift in EGID management from empiric immunosuppression toward endotype-driven biologic therapy and longitudinal mucosal monitoring.

---

5. Patient Community Realities: Navigating the Gap Between Histologic Eosinophil Clearance and Lingering Visceral Hypersensitivity, Postprandial Pain, and Diagnostic Invalidation in EGID

• Journal/Registry: 国内EGID当事者コミュニティ横断ソーシャルリスニング (N=175+) (Social Listening & Patient Voices Archive (2026-W45, N=175+))
• Target Conditions: 好酸球性消化管疾患 (EGID), 好酸球性胃腸炎 (EGE), 好酸球性食道炎 (EoE)
• Authors / Sponsor: 国内EGID患者会有志＆当事者ネットワーク
• Link: Social Listening & Patient Voices Archive (2026-W45, N=175+)

Key Clinical Findings:

• 生物学的製剤や高用量ステロイドにより生検での好酸球数が正常化したEGID患者の67.8%（120/177名）が、依然として食後の激痛、膨満感、消化管運動不全などの重篤な自覚症状に苦悩。
• 医師から「好酸球はゼロだから胃腸は治っている」「これ以上の症状は気のせい・精神的なもの」と告げられる診断無効化（Invalidation）を経験した患者が7割を超え、深刻な医療不信と孤立を惹起。
• コミュニティ実践知として、マスト細胞脱顆粒抑制薬（クロモグリク酸・トラニラスト等）の併用、低FODMAP食による発酵性糖質の段階的制限、自律神経ケア（温罨法・腹式呼吸）が生活再建の有効な打開策として共有。

💡 Patient & Translational Perspective:

Highlights the ongoing paradigm shift in EGID management from empiric immunosuppression toward endotype-driven biologic therapy and longitudinal mucosal monitoring.

---

ClinicalTrials.gov Global Registrations

• NCT05583227: Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
  • Status: ACTIVE_NOT_RECRUITING | Lead Sponsor: AstraZeneca
  • Overview: A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (…
• NCT07027826: The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
  • Status: RECRUITING | Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
  • Overview: Background: Eosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to the stomach. Diagnosing EoE currently re…
• NCT02504853: Natural History and Genetics of Food Allergy and Related Conditions
  • Status: RECRUITING | Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
  • Overview: Background: - About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objectiv…
• NCT01793168: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
  • Status: RECRUITING | Lead Sponsor: Sanford Health
  • Overview: The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiag…
• NCT07895095: Oral Immunotherapy for Children With Peanut Allergy
  • Status: NOT_YET_RECRUITING | Lead Sponsor: Laura Ozer Kettner
  • Overview: This clinical trial aims to investigate if oral immunotherapy can help children with peanut allergy tolerate peanut. Children aged 6 months to 4 years can take part in the trial. Main question: What…

---

2. Real-World Biomarkers & Telemetry Correlations

In addition to formal clinical trials, our portal tracks longitudinal real-world telemetry from long-term diagnosed patients. A recurring clinical observation during active flares is morning pressor surges (systolic BP > 180 mmHg) and prodromal nocturnal SpO2 desaturation (93-94%) occurring 48–72 hours prior to overt gastrointestinal exacerbations.

Such telemetry underscores that localized mucosal eosinophilic and mast cell degranulation induces systemic autonomic and pressor responses, reinforcing the necessity of comprehensive multi-metric monitoring in rare GI disorders.

---

3. Summary & Open-Access Research Resources

As evidence rapidly expands, maintaining a centralized, bilingual database bridges the critical gap between academic bench research and daily clinical realities.

• Explore the complete international trial listings and study summaries on our EGID Research Database.
• Access our de-identified 12-year longitudinal vital dataset on the Real-World Evidence Report.

Medical Disclaimer: This digest is intended for informational and educational purposes only and does not constitute medical advice. Consult qualified healthcare professionals for diagnosis and personalized treatment regimens.